OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

KRAS G12C-mutant colorectal cancer: lines of therapy

Cancer page →

3 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Advanced, first line2
Third line and beyond1

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic, previously treatedSotorasib plus panitumumab (CodeBreaK 300) or adagrasib plus cetuximab (KRYSTAL-1) after fluoropyrimidine, oxaliplatin and irinotecan.
CodeBreaK 300Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1SotorasibPanitumumabAdagrasibCetuximabKRAS & RAS inhibitors
93
All comersMetastatic, first lineFOLFOX, FOLFIRI or CAPOX with bevacizumab, as for any RAS-mutant colorectal cancer; anti-EGFR antibodies are not used; KRAS G12C combinations are under test first line (CodeBreaK 301).
FOLFOX (5-FU, leucovorin, oxaliplatin)FOLFIRI (5-FU, leucovorin, irinotecan)CAPOX (capecitabine, oxaliplatin)BevacizumabStudy of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal
98

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
All comersLater linesTrifluridine-tipiracil with bevacizumab (SUNLIGHT), fruquintinib (FRESCO-2) or regorafenib; clinical trials of next-generation RAS inhibitors.
SUNLIGHTFRESCO-2Trifluridine/tipiracilFruquintinibRegorafenib
94

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.